Alpha-O Peptides AG

Alpha-O Peptides AG (“AOP”) is a Swiss nano-biotechnology company focusing on the development of potent vaccines based on repetitive antigen display technology using our proprietary and patented self-assembling protein nanoparticles (SAPNs). AOP’s most advanced vaccine has demonstrated complete protection against malaria infection in an animal model. The National Institutes of Health (NIH) and the U.S. Military Infectious Disease Research Program have both supported this project.